http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013531651-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7455 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04 |
| filingDate | 2010-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013531651-A |
| titleOfInvention | Treatment of coagulopathy with increased fibrinolysis |
| abstract | The present invention relates to the use of thrombomodulin analogues for the manufacture of a medicament for the treatment of coagulation disorders with increased fibrinolysis, such as hemophilia. These thrombomodulin analogs exhibit an antifibrinolytic effect at therapeutically effective dosages. Novel protein modifications are disclosed along with their identification methods. The present invention provides particularly suitable pharmaceutically active proteins and peptides that can be used, for example, according to the present invention. In accordance with one embodiment of the present invention, a thrombomodulin analog of the present invention having reduced binding affinity for thrombin compared to rabbit lung thrombomodulin can be used for the treatment of coagulopathy with hyperfibrinolysis. |
| priorityDate | 2010-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 221.